ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT03742921 COMPLETED

To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax. 1. Planned registration period 4 years 2. Planned surveillance period 5 years and 6 months

Details

Lead sponsor	Celgene
Status	COMPLETED
Enrolment	150
Start date	Mon Feb 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Oct 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Lymphoma, T-Cell, Peripheral

Interventions

• Istodax

Countries

Japan